Abstract
Cyclophosphamide and ifosfamide are commonly used anticancer agents. A major limiting factor in their use is the resulting bladder toxicity which can result in ongoing bladder pain, urgency and dysuria. These drugs and their metabolites come into contact with the urothelium when they are excreted in the urine, potentially damaging the urothelium.
| Original language | English |
|---|---|
| Pages | 206-206 |
| Number of pages | 1 |
| Publication status | Published - 2012 |
| Event | Joint ASCEPT- APSA 2012 Conference : Medication Safety - Sydney Convention and Exhibition Centre, Sydney, Australia Duration: 2 Dec 2012 → 5 Dec 2012 http://www.ascept-apsa.com/ |
Conference
| Conference | Joint ASCEPT- APSA 2012 Conference |
|---|---|
| Country/Territory | Australia |
| City | Sydney |
| Period | 2/12/12 → 5/12/12 |
| Internet address |
Fingerprint
Dive into the research topics of 'Effects of acrolein, a metabolite of Cyclophosphamide and Ifosfamide, on cultured human urothelial cells'. Together they form a unique fingerprint.Student theses
-
Cyclophosphamide and ifosfamide: mechanisms of cytotoxic action and consequences for normal bladder function
Author: Mills, K., 10 Oct 2015Supervisor: Chess-Williams, R. G. (Supervisor) & McDermott, C. (Supervisor)
Student thesis: Doctoral Thesis
File